Aditxt (NASDAQ: ADTX) previously entered into a definitive agreement to acquire Evofem Biosciences Inc. (OTCQB: EVFM), which is believed to represent a compelling opportunity to accelerate Evofem’s growth trajectory, as a subsidiary of Aditxt, into a multi-product women’s health franchise. Today Evofem, the company behind Phexxi(R) (lactic acid, citric acid and potassium bitartrate) vaginal gel, announced financial results for the fourth quarter and year ended Dec. 31, 2023. Among the highlights, the company reported $18.2 million of Phexxi net product sales in 2023, an impressive increase compared to 2022 given the 73% reduction in field force and absence of growth capital in 2023. “Our ongoing revenue growth and improved loss from operations testifies to the strength and persistence of Evofem’s current sales team, the growing base of users and prescribers of Phexxi nationwide, and the continued expansion of coverage and reimbursement,” said Saundra Pelletier, CEO of Evofem Biosciences.
To view the full press release, visit https://ibn.fm/zX4Or
About Aditxt Inc.
Aditxt is focused on discovering, developing and deploying promising health innovations. Aditxt’s diverse portfolio includes Adimune(TM), developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity and allergies; Adivir(TM), focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta(TM), offering timely, convenient and high-quality personalized lab testing anytime and anywhere, backed by its CLIA-certified and CAP-accredited monitoring center. For more information, visit the company’s website at www.Aditxt.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com
InvestorWire is powered by IBN
